Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19

Sarah Lim; Christopher J Tignanelli; Nicolas Hoertel; David R Boulware; Michael G Usher

doi:10.1093/ofid/ofac389

Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19

Open Forum Infect Dis. 2022 Aug 3;9(8):ofac389. doi: 10.1093/ofid/ofac389. eCollection 2022 Aug.

Authors

Sarah Lim¹, Christopher J Tignanelli², Nicolas Hoertel³, David R Boulware⁴, Michael G Usher⁴

Affiliations

¹ Minnesota Department of Health, St. Paul, Minnesota, USA.
² Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
³ Université Paris Cité, AP-HP, Hôpital Corentin-Celton, DMU Psychiatrie et Addictologie, INSERM U1266, Institut de Psychiatrie et Neuroscience de Paris, Paris, France.
⁴ Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.

Abstract

This analysis describes the prevalence of contraindications to nirmatrelvir/ritonavir among 66 007 patients with coronavirus disease 2019 in a large health care system. A possible contradiction was present in 9830 patients (14.8%), with the prevalence of contraindications increasing with higher acuity of illness.

Keywords: COVID-19; Palovid; contraindications; nirmatrelvir/ritonavir.